Cardiotoxicity Low for Patients Receiving Paclitaxel, Trastuzumab for ERBB2+ Breast Cancer

Share this content:
Cardiac toxic effects from paclitaxel with trastuzumab were low in patients with node-negative, ERBB2-positive breast cancer.
Cardiac toxic effects from paclitaxel with trastuzumab were low in patients with node-negative, ERBB2-positive breast cancer.

Cardiac toxic effects from paclitaxel with trastuzumab, presenting as grade 3 or 4 left ventricular systolic dysfunction (LVSD) or asymptomatic left ventricular ejection fraction decline (LVEF), were low in patients with node-negative, ERBB2-positive breast cancer, a new study published online ahead of print in JAMA Oncology has shown.1

Although trastuzumab is a life-saving therapy for many patients with ERBB2- (formerly human epidermal growth factor receptor 2 [HER2]) positive breast cancer, it is often associated with symptomatic and asymptomatic left ventricular ejection fraction (LVEF) decline.

Therefore, researchers sought to evaluate the cardiotoxic effects of a trastuzumab-based treatment without an anthracycline for early stage ERBB2-positive breast cancer.

Researchers analyzed data from an uncontrolled, single-group study that enrolled 406 patients with node-negative, ERBB2-positive breast cancer that was 3 cm or smaller, and baseline LVEF 50% or higher.

Patients with a micrometastasis in a lymph node were also eligible to participate. All patients received adjuvant weekly paclitaxel for 12 weeks with trastuzumab, followed by trastuzumab monotherapy at a dose of 2 mg/kg weekly or 6 mg/kg every 3 weeks. Researchers assessed participants' LVEF at baseline, 12 weeks, 6 months, and 1 year.

RELATED: Breast Cancer Question-and-Answer Session With Charles Vogel, MD

Results showed that overall, only 0.5% (95% CI, 0.1 – 1.8) of patients developed grade 3 LVSD and 3.2% (95% CI, 1.9 – 5.4) developed significant asymptomatic LVEF decline. Researchers found that median LVEF at baseline was 65% and was 64% at 12 weeks, 6 months, and 1 year.

“Our findings suggest that LVEF monitoring during trastuzumab therapy without anthracyclines could be simplified for many individuals,” the authors concluded.

Reference

  1. Dang C, Guo H, Najita J, et al. Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer [published online ahead of print November 5, 2015]. JAMA Oncol. doi: 10.1001/jamaoncol.2015.3709.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters